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HM2
MODELS IDENTIFYING VARIABLES INFLUENCING PHYSICIAN
ADOPTION OF NEWLY LAUNCHED PHARMACEUTICALS IN
THE UNITED STATES
Mayo KW, Glass H, Lee D
University of the Sciences in Philadelphia, Philadelphia, PA, USA
OBJECTIVE: An absence of the understanding of the variables
inﬂuencing physician prescribing behavior has limited the ability
of pharmaceutical manufacturers to optimize resources dedi-
cated to marketing newly launched products. This investigation
ﬁlls a void by investigating the relative inﬂuence of ﬁve sets of
predictors upon the likelihood of a physician to adopt a new
product. METHODS: The prescribing behavior of 3646 physi-
cians was examined for the ﬁrst 18 months after drug launch for
32 new drugs in 7 chronic disorders entering the market between
1997 and 2000. Two OLS regression models were derived—one
examining innovative, ﬁrst in class, drugs and the other exam-
ining follow-on products. The models utilized two dependent
variables, the total number of prescriptions written for the new
drug in the 18 months following launch and the incremental
number of prescriptions written by the physician from the
company marketing the new product. RESULTS: The models
examined the relative importance of ﬁve types of variables,
physician demographics, physician practice data, physician pre-
scribing patterns prior to the new product launch, level of mar-
keting support from the launch company and the relative
product price. The relative importance of the variables differed
appreciably between the two type drugs. CONCLUSIONS:
Physician Pre-Launch Company Prescribing Loyalty is the most
signiﬁcant predictor of the adoption of innovative drugs, while
Marketing Power and Price are the most signiﬁcant predictors of
the adoption of follow on products. This investigation provides
OLS regression models for the optimization of marketing
resources.
HM3
PREDICTING PHARMACY COSTS USING HEALTH-RELATED
QUALITY-OF-LIFE AND PHARMACY CLAIMS MEASURES IN
ADULT ASTHMATICS
Meyer C, Liberman J, Cooper D, Kalmanowicz J, Chaudry S
AdvancePCS, Hunt Valley, MD, USA
OBJECTIVE: To investigate if a health-related quality of life
(HRQOL) measure can predict pharmacy costs in insured adult
asthmatics independently and in conjunction with a baseline
pharmacy claims risk index and prior pharmacy costs.
METHODS: Historical cohort analysis of pharmacy claims and
HRQOL. Asthmatics were invited to complete the SF-36 quality
of life instrument between May 12, 2001 and November 30,
2002. Pharmacy claims for the year prior to this interview were
used to derive baseline measures of the AdvancePCS pharmacy
claims health risk index and prior pharmacy costs. The study’s
outcome measure, pharmacy costs in the year following the base-
line interview, was calculated for those who remained eligible for
pharmacy beneﬁts during the entire study period. Correlation
statistics were calculated. Linear regression modeling evaluated
the association between the outcome measure and each SF-36
domain, the risk index, prior costs, member sex, and age at base-
line. RESULTS: A population of 247 adult asthmatics from a
million-member, Mid-Atlantic health plan was included. Follow-
up year pharmacy costs were moderately correlated with the
pharmacy risk index (Spearman +0.576, p < 0.001) and weakly
negatively correlated with the physical summary score (Spear-
man -0.340, p < 0.001). However, prior pharmacy costs had the
strongest correlation (Spearman +0.87, p < 0.001). The physical
summary score was a signiﬁcant predictor of next year’s phar-
macy costs (Coefﬁcient -110.92; p < 0.001) after adjustment for
age in linear models (R2 = 0.134). However including the phar-
macy risk index (Coefﬁcient 72.770; p = 0.06) and prior phar-
macy costs (Coefﬁcient 0.948; p < 0.001) vastly improved the
explanation of variation in follow-up pharmacy costs (R2 =
0.774) and eliminated the independent signiﬁcant effect of the
physical summary score (Coefﬁcient -8.236, p = 0.518). Similar
removal of signiﬁcance occurred with other SF-36 domains after
adjusting for claims measures. CONCLUSIONS: While HRQOL
independently predicts follow-up costs, it does not improve pre-
dictive models using prior pharmacy utilization in this study
population of adult asthmatics.
HM4
HOW ROBUST IS COST-EFFECTIVENESS RATIO TO MISSING
DATA IMPUTATION? ANALYSIS OF LONG-TERM CLINICAL
TRIAL IN PARKINSONS DISEASE
Noyes K, Holloway RG, Dick AW
University of Rochester School of Medicine, Rochester, NY, USA
OBJECTIVES: Subject attrition is unavoidable in long-term clin-
ical trials. Using various assumptions about missing data, this
study estimates incremental cost-effectiveness ratios (ICERs) and
welfare (W) consequences of two drug therapies in patients with
early Parkinson’s disease (PD). METHODS: Three hundred one
subjects with PD were randomized to initial pramipexole or lev-
odopa and followed every 3-months over a 4-year period. Health
care resource use was measured and costed using a variety of
sources. Quality of life (Qol) was measured using a visual analog
scale. Using a multivariate ﬁxed effects model, we imputed
missing Qol and cost data and calculated the 4-year total QALYs
and costs for each treatment arm. The ICER and the welfare (W)
estimates, using $50K as a cost of QALY, were bootstrapped to
calculate the standard errors. We conducted a sensitivity analy-
sis on the ICER and the W under optimistic and pessimistic
assumptions of a subject’s Qol after dropout based on the trends
estimated from the multivariate analysis. The slope of the post-
dropout Qol was modiﬁed based on the beta coefﬁcient for the
dummy variable indicating last visit before dropout. RESULTS:
The base case cost-effectiveness was $32,107/QALY and welfare
enhancement due to initial pramipexole versus levodopa was
$2748 (SD 4526). If subjects were to decline after dropout, the
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ICER would be $53,964/QALY and the W would be $-362 (SD
3322). If the subjects were to improve after dropout, the ICER
would be $29,475/QALY and the W would be $3434 (SD 3309).
CONCLUSIONS: The results of cost-effectiveness analysis are
fairly robust to the choice of imputation scenario. While point
estimates indicate that over 4 years pramipexole is a cost-
effective alternative to levodopa, signiﬁcant statistical uncer-
tainty exists. The uncertainty associated with the assumptions
regarding post-dropout Qol is dwarfed by the uncertainty asso-
ciated with the ICER estimate.
SCREENING
SC1
PATIENT PREFERENCES FOR COLORECTAL CANCER (CRC)
SCREENING STRATEGIES
Marshall DA1, Marshall JK1, Phillips KA2, Johnson RF3,Thabane L1,
Foster G1, O’Brien B1
1McMaster University, Hamilton, ON, Canada; 2University of California
San Francisco, San Francisco, CA, USA; 3Research Triangle Institute,
NC, USA
The success of population screening for CRC depends largely on
public uptake. Available strategies differ in multiple dimensions
of process and outcome. OBJECTIVE: To measure patient pref-
erences for CRC screening attributes and estimate willingness to
pay (WTP) for changes in attribute levels using a discrete choice
experiment (“conjoint analysis”). METHODS: Six key attributes
of CRC screening strategies were identiﬁed through structured
focus groups. Questionnaires included 10 choice sets based on a
fractional factorial design to maximize D efﬁciency. Surveys 
were mailed to a random sample of patients aged 40–60 years
from an Ontario primary care network (response rate = 51%
(547/1074), 88% of whom completed all 10 choice sets (n =
485)); b coefﬁcients from regression analyses estimated the mar-
ginal utilities of attribute levels from which WTP was calculated.
Differences among subgroups were tested using likelihood ratio
tests. RESULTS: Respondents had the strongest preferences for
sensitivity, with the highest utility for high sensitivity and the
lowest utility for low sensitivity. Individuals would be willing to
pay an additional CDN$910 (~US$640) for a test with high vs.
low sensitivity. Following sensitivity, respondents had the highest
preferences (in descending order) for speciﬁcity, preparation,
pain, and price. Preferences differed signiﬁcantly by gender, age
(<50yrs vs. >50yrs), income (<$50,000 vs. >$50,000) and edu-
cation (high school or less versus college or higher). In follow-
up questions for each choice set where individuals were asked if
they would prefer no test, 26% of respondents chose no testing
in more than 5 of their 10 choice sets. CONCLUSIONS: Results
show a wide range of marginal utility for attribute levels of CRC
screening tests, and many respondents preferred no test. Better
understanding of patient preferences can help improve the
design, promotion and uptake of CRC screening programs.
SC2
COST EFFECTIVENESS OF SCREENING AND STATIN
THERAPY IN CLINICAL GUIDELINES FOR CARDIOVASCULAR
PROPHYLAXIS
Milne RJ, Gamble GD
University of Auckland, Auckland, New Zealand
OBJECTIVES: To quantify the cost effectiveness of updated clin-
ical guidelines for risk screening and prevention of cardiovascu-
lar disease (CVD) with “statin” therapy in individuals free of
cardiovascular disease. METHODS: Risk proﬁles were collected
in 1992–1993 for 4704 men age 35–84y and 1216 women age
45–84y without CVD. Five-year risk of a cardiovascular hospi-
tal admission for each individual was estimated using a locally
validated Framingham risk equation. The predicted number of
incident events in 5 years was scaled to the 2001 NZ census pop-
ulation and integrated over age groups. In the base case, costs,
beneﬁts and cost effectiveness were estimated at screening age
thresholds of 45 for men and 55 for women (10 years younger
for smokers); concurrent treatment thresholds of 15% 5-year
cardiovascular risk and TC/HDLc = 4.5; and 5% discount rate.
RESULTS: In the NZ population of 784K men age 35–84y and
558K women age 45–84y, 72K men and 53K women would be
eligible for prophylaxis. Compared to no intervention, 5y pro-
phylaxis with 84% treatment adherence at a 15% treatment
threshold would avert 6716 incident cardiovascular events and
add 17,205 life years or 21,317 QALYs at an incremental cost
of $NZ70M. The base case ICER is $10,459 per event avoided,
$4083 per LYG or $3295 per QALY and it is sensitive to the
threshold lipid ratio, screening and treatment ages, risk thresh-
old, treatment efﬁcacy, 5y cardiovascular fatality, statin unit
price and the discount rate. CONCLUSIONS: Screening and
prophylaxis with statins is very cost effective at current drug
prices and clinically realistic screening and treatment thresholds.
SC3
FACTORS IMPACTING MAMMOGRAPHY SCREENING IN
RURAL AND URBAN AREAS
Khan N
University of Illinois at Chicago, Chicago, IL, USA
OBJECTIVE: To compare mammography screening in rural and
urban areas and to assess the effect of various predisposing and
enabling factors on mammography screening. METHODS: Ret-
rospective self-reported cross-sectional data from Behavioral
Risk Factor Surveillance System (BRFSS) for year 2000 along
with county level contextual variables from area resource ﬁle
(ARF) were used in the analysis. The analysis was restricted to
females between 40–69 years of age. Logistic regression analysis
was performed using an indicator of mammography screening as
a dependent variable and race, age, rural dummy as independent
variables. Series of multiple logistic regressions adding predis-
posing and enabling factors consecutively to this model were
conducted. All the results were adjusted for complex survey
design. RESULTS: Seventy eight percent of women reported
having had a mammography within the last two years for routine
check up. Women living in rural area were less likely to be
screened for mammography as compared to women residing in
urban areas (OR = 0.80, CI = 0.72–0.86). This difference in
screening no longer persisted after controlling for predisposing
(smoking status, education level), enabling (income, insurance
status) and contextual level enabling factors (physician popula-
tion ratio). In general, women with higher education and better
ﬁnancial condition were more likely to screen. CONCLUSIONS:
Insurance status was one of the major determinants of mam-
mography screening for females residing in rural area. Avail-
ability of health care services also had an impact on screening
rates. In an environment where rural areas are faced with short-
age of health care services, the active participation of health care
workers like physicians in advocating use of screening services
becomes crucial.
SC4
ECONOMIC EVALUATION OF SCREENING FOR THE A-
ADDUCIN GENE VARIANT IN HYPERTENSIVE PATIENTS
Meckley LM,Veenstra DL
University of Washington, Seattle, WA, USA
OBJECTIVES: The purpose of this study was to determine
whether screening for the a-adducin gene variant among hyper-
